

Bobbi J Woolwine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/918815/publications.pdf>

Version: 2024-02-01

37
papers

5,456
citations

147801

31
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

5788
citing authors

#	ARTICLE	IF	CITATIONS
1	Kynurenines increase MRS metabolites in basal ganglia and decrease resting-state connectivity in frontostriatal reward circuitry in depression. <i>Translational Psychiatry</i> , 2021, 11, 456.	4.8	8
2	Transcriptomic signatures of psychomotor slowing in peripheral blood of depressed patients: evidence for immunometabolic reprogramming. <i>Molecular Psychiatry</i> , 2021, 26, 7384-7392.	7.9	15
3	543 - Cultural Considerations for Older LGBTQ Adults During the COVID-19 Pandemic: Case and Review. <i>International Psychogeriatrics</i> , 2021, 33, 85-86.	1.0	0
4	What does plasma CRP tell us about peripheral and central inflammation in depression?. <i>Molecular Psychiatry</i> , 2020, 25, 1301-1311.	7.9	251
5	Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 193-202.	4.1	21
6	Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. <i>Neuropsychopharmacology</i> , 2020, 45, 998-1007.	5.4	101
7	Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 161-165.	4.1	42
8	Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. <i>Psychoneuroendocrinology</i> , 2018, 98, 222-229.	2.7	44
9	Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. <i>Translational Psychiatry</i> , 2018, 8, 189.	4.8	78
10	Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. <i>Psychoneuroendocrinology</i> , 2018, 95, 43-49.	2.7	186
11	Inflammation negatively correlates with amygdala-ventromedial prefrontal functional connectivity in association with anxiety in patients with depression: Preliminary results. <i>Brain, Behavior, and Immunity</i> , 2018, 73, 725-730.	4.1	81
12	Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. <i>Brain, Behavior, and Immunity</i> , 2016, 56, 281-288.	4.1	102
13	Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. <i>Physiology and Behavior</i> , 2016, 166, 14-21.	2.1	38
14	Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings. <i>Brain, Behavior, and Immunity</i> , 2015, 46, 17-22.	4.1	56
15	Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. <i>Brain, Behavior, and Immunity</i> , 2015, 47, 193-200.	4.1	59
16	IFN-Alpha-Induced Cortical and Subcortical Glutamate Changes Assessed by Magnetic Resonance Spectroscopy. <i>Neuropsychopharmacology</i> , 2014, 39, 1777-1785.	5.4	130
17	Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations. <i>Brain, Behavior, and Immunity</i> , 2013, 31, 153-160.	4.1	146
18	Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. <i>Brain, Behavior, and Immunity</i> , 2013, 31, 205-215.	4.1	57

#	ARTICLE	IF	CITATIONS
19	A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression. <i>JAMA Psychiatry</i> , 2013, 70, 31.	11.0	1,314
20	Neurobehavioral Effects of Interferon- α in Patients with Hepatitis-C: Symptom Dimensions and Responsiveness to Paroxetine. <i>Neuropsychopharmacology</i> , 2012, 37, 1444-1454.	5.4	51
21	Dopaminergic Mechanisms of Reduced Basal Ganglia Responses to Hedonic Reward During Interferon Alfa Administration. <i>Archives of General Psychiatry</i> , 2012, 69, 1044.	12.3	306
22	Molecular signatures of peripheral blood mononuclear cells during chronic interferon- α treatment: relationship with depression and fatigue. <i>Psychological Medicine</i> , 2012, 42, 1591-1603.	4.5	53
23	Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1094-1098.	4.1	38
24	Interferon- α effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. <i>Molecular Psychiatry</i> , 2010, 15, 535-547.	7.9	164
25	CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN- α : relationship to CNS immune responses and depression. <i>Molecular Psychiatry</i> , 2010, 15, 393-403.	7.9	546
26	Chronic Interferon-Alpha Administration Disrupts Sleep Continuity and Depth in Patients with Hepatitis C: Association with Fatigue, Motor Slowing, and Increased Evening Cortisol. <i>Biological Psychiatry</i> , 2010, 68, 942-949.	1.3	106
27	Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression. <i>Biological Psychiatry</i> , 2009, 65, 296-303.	1.3	315
28	Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon- α Therapy. <i>Neuropsychopharmacology</i> , 2007, 32, 2384-2392.	5.4	203
29	Paroxetine for prevention of depressive symptoms induced by interferon- α and ribavirin for hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1163-1174.	3.7	130
30	Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study. <i>Journal of Psychiatric Research</i> , 2006, 40, 669-676.	3.1	29
31	Promoter Polymorphisms of the Interferon- α Receptor Gene and Development of Interferon-Induced Depressive Symptoms in Patients with Chronic Hepatitis C: Preliminary Findings. <i>Neuropsychobiology</i> , 2005, 52, 55-61.	1.9	32
32	Depressive symptoms and viral clearance in patients receiving interferon- α and ribavirin for hepatitis C. <i>Brain, Behavior, and Immunity</i> , 2005, 19, 23-27.	4.1	137
33	Anterior Cingulate Activation and Error Processing During Interferon-Alpha Treatment. <i>Biological Psychiatry</i> , 2005, 58, 190-196.	1.3	204
34	Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 41-48.	2.2	262
35	Relationship of Clinical Symptoms and Substance Use in Schizophrenia Patients on Conventional Versus Atypical Antipsychotics. <i>American Journal of Drug and Alcohol Abuse</i> , 2003, 29, 553-566.	2.1	29
36	Increased Early Life Stress and Depressive Symptoms in Patients With Comorbid Substance Abuse and Schizophrenia. <i>Schizophrenia Bulletin</i> , 2002, 28, 223-231.	4.3	48

#	ARTICLE	IF	CITATIONS
37	Double Jeopardy: Schizophrenia and Substance Use. American Journal of Drug and Alcohol Abuse, 2000, 26, 343-353.	2.1	73